Opus Genetics (IRD) vs Kyverna Therapeutics (KYTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Opus Genetics (IRD) has outperformed Kyverna Therapeutics (KYTX) over the past year, gaining 117.2% versus a gain of 14.0%. Kyverna Therapeutics is the larger company by market cap ($381.0 million vs $368.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRD | KYTX |
|---|---|---|
| Share price | $4.43 | $6.16 |
| Market cap | $368.56M | $380.96M |
| 1-day change | +0.45% | -0.16% |
| YTD return | +119.40% | -34.36% |
| 1-year return | +117.24% | +14.05% |
| 5-year return | +2.80% | — |
| EPS (TTM) | $-1.27 | $-2.93 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.07 | $13.67 |
| 52-week low | $1.70 | $5.96 |
| Distance from 52-week high | -37.34% | -54.94% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +202.71% | +393.51% |
| Average volume | 2.37M | 898.60K |
| Shares outstanding | 83.20M | 61.84M |
| Employees | 27 | 149 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IRD has outperformed KYTX by 103.2 percentage points over the past year.
About Opus Genetics
IRD stock →Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
About Kyverna Therapeutics
KYTX stock →Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 149 employees
IRD vs KYTX FAQ
Which is bigger, Opus Genetics or Kyverna Therapeutics?
Kyverna Therapeutics (KYTX) is larger, with a market capitalization of $380.96M compared with $368.56M for Opus Genetics (IRD).
Which stock has performed better over the past year, IRD or KYTX?
IRD returned +117.24% over the past 12 months, compared with +14.05% for KYTX (price return, excluding dividends). Past performance does not predict future results.
Are Opus Genetics and Kyverna Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Opus Genetics and Biotechnology: Biological Products (No Diagnostic Substances) for Kyverna Therapeutics.